MYDX - MyDx, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0025
+0.0001 (+5.26%)
At close: 3:50PM EDT
Stock chart is not supported by your current browser
Previous Close0.0024
Open0.0024
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0022 - 0.0026
52 Week Range0.0020 - 0.0110
Volume4,082,464
Avg. Volume7,253,144
Market Cap9.694M
Beta-5.41
PE Ratio (TTM)N/A
EPS (TTM)-0.0020
Earnings DateNov 24, 2017 - Nov 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile4 days ago

    MyDx Shareholder Update

    A Leader in Science-Based Cannabis Health Technologies Positioning for a Pharma Acquisition San Diego, California--(Newsfile Corp. - September 21, 2018) - MyDx, Inc. (OTC Pink: MYDX), a leader in science-based cannabis health technologies, has been working diligently over the past four months on implementing a strategy designed to have it become a highly desired acquisition target for big pharma or another entity interested in the powerful data MyDx is accumulating in the emerging global ...

  • GlobeNewswire4 days ago

    MyDx Shareholder Update

    MyDx has continued to see further geographical penetration and market adoption of the CannaDx Analyzer with continued sales in the US and Canada as well as new countries coming online as Cannabis becomes more popular globally. Amongst our growing demographic of customers, we have received orders from government agencies such as the Department of Fish & Wildlife as well as from a major university that plans to use the CannaDx Analyzer and App in their upcoming HIV study.

  • Newsfile5 days ago

    MyDx Announces 2018 First Quarter Results

    MyDx Reports Positive Net Income as it Positions Itself for Growth and Investment San Diego, California--(Newsfile Corp. - September 19, 2018) - MyDx, Inc. (OTC Pink: MYDX), a leader in science based cannabis health technologies and creator of the industry's first handheld analyzer to help consumers and professionals understand how cannabis makes cannabis users feel,today announces its 2018 first quarter earnings results and management analysis.MyDx reported positive earnings of $880k in the first quarter of 2018 as it ...

  • MyDx Secures City and State Legal Cannabis Manufacturing and Distribution for Its MyDx360 Customers
    Newsfile5 days ago

    MyDx Secures City and State Legal Cannabis Manufacturing and Distribution for Its MyDx360 Customers

    MyDx360 Customers in California Now Have Access to One of the First Legally Licensed Cannabis Manufacturing and Distribution Facilities Located in the City of San Diego San Diego, California--(Newsfile Corp. - September 19, 2018) - MyDx, Inc. (OTC Pink: MYDX) ("MyDx" or the "Company"), a leader in science based cannabis health technologies and creator of the industry's first handheld, multi-use chemical analyzer to help consumers and professionals understand how cannabis makes cannabis users feel, announced ...

  • Newsfile5 days ago

    Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran, Joins MyDx Executive Advisory Board

    Dr. Dreismann To Also Serve as Chairman of the Executive Advisory Board; Assist MyDx In Seeking Development Partners and Strategic Partners San Diego, California--(Newsfile Corp. - September 19, 2018) - MyDx, Inc. (OTC Pink: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to understand the chemical profile of cannabis with how it makes them feel and which ailments it ...

  • Newsfile5 days ago

    MyDx Announces 2017 Fiscal Year Results

    Gross Profit Margin Surged to 73% with Gross Profits Remaining Relatively Flat at ~$306K as MyDx Continues to Execute on its Long-Term Strategy San Diego, California--(Newsfile Corp. - September 19, 2018) - MyDx, Inc. (OTC Pink: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments ...

  • The Biggest Lie In Cannabis
    PR Newswire7 months ago

    The Biggest Lie In Cannabis

    MyDx entered into an agreement to provide a licensor with access to its dataset in order to come up with a "Counterfeit Index" that determines the likelihood that a strain name doesn't tie to its chemical profile. The counterfeit index will identify and rank the strain names that have the greatest deviation in chemical profile which is often the result of intentionally mislabeling strains with names that gain extreme popularity in order to yield a greater price per gram. Since popular names yield higher prices, the index plans to inform consumers to demand confirmation of the chemical profile to ensure they're getting what they paid for.

  • The Biggest Lie In Cannabis
    CNW Group7 months ago

    The Biggest Lie In Cannabis

    The Biggest Lie In Cannabis

  • MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula
    CNW Group8 months ago

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

  • MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula
    PR Newswire8 months ago

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

    Partnering with the Leading Israeli Research and Development Organizations and Hospitals Devoted to the Scientific Study of Cannabis SAN DIEGO , Jan. 16, 2018 /PRNewswire/ --  MyDx, Inc.  (OTCQB: MYDX), ...

  • MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula
    PR Newswire8 months ago

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

    SAN DIEGO, Jan. 16, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to understand the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced a definitive agreement and statement of work with a contract research organization to commence clinical trials in Israel on its proprietary pain management formula that was derived from 50,000+ pre-clinical, crowd-sourced physiological data-points tracked by MyDx's Handheld Cannabis Tester and associated mobile app.

  • MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer
    PR Newswire8 months ago

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

    Board Certified Internal Medicine Doctor to Lead MyDx Clinical Research Initiatives and Support MyDx360 Formulations Services SAN DIEGO , Jan. 11, 2018 /PRNewswire/ --  MyDx, Inc. (OTC: MYDX), a science ...

  • MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer
    CNW Group8 months ago

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

  • PR Newswire8 months ago

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

    SAN DIEGO, Jan. 11, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has recruited Dr. Jessica Peatross (Dr. Jess) as its Chief Medical Officer. Dr. Jess will lead the Clinical Research Initiatives that MyDx expects to begin soon as well as support formulation services offered to MyDx360 Customers. Dr. Jessica Peatross is a western trained, board certified medical doctor and Gerson Therapy practitioner who began her journey into healing in 2009 when she graduated from the University of Louisville (KY) Internal Medicine residency program.

  • MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects
    PR Newswire9 months ago

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

    SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has agreed on terms and entered into a Letter of Intent to partner with Highsmen Genetics to form a new Exclusive Joint Venture. The technology behind Highsmen to develop stable customized genetic strains for certain effects is expected to help MYDX360 customers realize additional brand loyalty through end-user input in the MyDx App that will now influence the flower breeding programs that power the product lines they are consuming.

  • MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects
    PR Newswire9 months ago

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

    SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has agreed on terms and entered into a Letter of Intent to partner with Highsmen Genetics to form a new Exclusive Joint Venture. The technology behind Highsmen to develop stable customized genetic strains for certain effects is expected to help MYDX360 customers realize additional brand loyalty through end-user input in the MyDx App that will now influence the flower breeding programs that power the product lines they are consuming.

  • MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects
    CNW Group9 months ago

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

  • MyDx Cancels Reverse Stock Split
    PR Newswire9 months ago

    MyDx Cancels Reverse Stock Split

    SAN DIEGO, Dec. 20, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that based upon recent and anticipated developments for the Company, the board has decided to cancel its plans for the reverse stock split approved earlier this year. "With the influx of interest for our MyDx360 services, including ancillary products such as the EcoSmartPenTM, as well as the progress we have made in the analysis of our 55K+ data points and the development of MyDx crowdsourced formulations, we are very optimistic about where the Company is headed into 2018.

  • MyDx Cancels Reverse Stock Split
    CNW Group9 months ago

    MyDx Cancels Reverse Stock Split

    MyDx Cancels Reverse Stock Split

  • MyDx Cancels Reverse Stock Split
    PR Newswire9 months ago

    MyDx Cancels Reverse Stock Split

    SAN DIEGO, Dec. 20, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that based upon recent and anticipated developments for the Company, the board has decided to cancel its plans for the reverse stock split approved earlier this year. "With the influx of interest for our MyDx360 services, including ancillary products such as the EcoSmartPen™, as well as the progress we have made in the analysis of our 55K+ data points and the development of MyDx crowdsourced formulations, we are very optimistic about where the Company is headed into 2018.

  • MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen
    PR Newswire9 months ago

    MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen

    SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it submitted an application and is seeking medical device designation in Canada for its CannaDxTM Handheld Tester and its ECOSmartPenTM in order to make its products more accessible to medicinal users seeking to track and manage their consumption habits and prevent abuse.